Medicinal cannabis manufacturer iX Biopharma has insisted it can and will continue to operate as a going concern despite the reservations of its auditor.
PricewaterhouseCoopers (PWC) said it was unable to obtain “sufficient appropriate evidence” in iX Biopharma’s full-year accounts to provide an audit opinion.
The speciality pharmaceutical and nutraceutical company, which is listed on the Singapore Stock Exchange, posted a loss in FY24 of S$10.79 million (A$12.28m) and operating outflows of S$6.55m. Current liabilities exceeded its assets by almost S$800,000, PWC said.
Continue reading...
